Veklury May Reduce Risk for Long COVID
Remdesivir (Veklury, Gilead) appears to reduce the risk for certain long-COVID symptoms in people who were hospitalized for COVID-19, according to data presented at CROI 2024, in Denver.
To understand remdesivir’s potential effect on the risk for long COVID, Gilead researchers analyzed HealthVerity data from 52,006 patients. They found using remdesivir, a nucleotide analog prodrug, was associated with a 10% lower risk for any long- COVID symptom in